Clearside Biomedical, Inc. (CLSD): Price and Financial Metrics


Clearside Biomedical, Inc. (CLSD)

Today's Latest Price: $1.95 USD

0.01 (-0.51%)

Updated Nov 27 1:00pm

Add CLSD to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CLSD Stock Summary

  • For CLSD, its debt to operating expenses ratio is greater than that reported by just 10.66% of US equities we're observing.
  • With a year-over-year growth in debt of -82.34%, Clearside Biomedical Inc's debt growth rate surpasses only 2.8% of about US stocks.
  • Revenue growth over the past 12 months for Clearside Biomedical Inc comes in at 3,664.37%, a number that bests 99.69% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Clearside Biomedical Inc are TRVN, KIN, MOTS, GBT, and OCX.
  • CLSD's SEC filings can be seen here. And to visit Clearside Biomedical Inc's official web site, go to www.clearsidebio.com.

CLSD Stock Price Chart Interactive Chart >

Price chart for CLSD

CLSD Price/Volume Stats

Current price $1.95 52-week high $4.13
Prev. close $1.96 52-week low $1.10
Day low $1.92 Volume 363,400
Day high $2.08 Avg. volume 516,347
50-day MA $1.53 Dividend yield N/A
200-day MA $1.83 Market Cap 94.29M

Clearside Biomedical, Inc. (CLSD) Company Bio


Clearside Biomedical, a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. The company was founded in 2011 and is based in Alpharetta, Georgia


CLSD Latest News Stream


Event/Time News Detail
Loading, please wait...

CLSD Latest Social Stream


Loading social stream, please wait...

View Full CLSD Social Stream

Latest CLSD News From Around the Web

Below are the latest news stories about Clearside Biomedical Inc that investors may wish to consider to help them evaluate CLSD as an investment opportunity.

Clearside Biomedical Announces Second Quarter 2020 Financial Results and Provides Corporate Update

- IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) -- Expanded Internal Suprachoroidal Pipeline with Two New Preclinical…

GlobeNewswire | August 10, 2020

Clearside Biomedical to Report Second Quarter 2020 Financial Results and Provide Corporate Update on Monday, August 10, 2020

ALPHARETTA, Ga., July 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its second quarter 2020 financial results will be reported on Monday, August 10, 2020 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domestic) or (213) 358-0959 (international) and entering conference code: 2290...

Yahoo | July 30, 2020

Clearside Biomedical Announces Multiple Presentations at the ASRS 2020 Virtual Annual Meeting

ALPHARETTA, Ga., July 27, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple posters and oral presentations on Clearside’s pipeline and its proprietary SCS Microinjector® targeting the suprachoroidal space (SCS®) were delivered at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting. “Clearside continues to stay top-of-mind with the ophthalmic and retina communities as our clinical development pipeline and suprachoroidal delivery system are featured at prominent medical meetings,” said Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development ...

Yahoo | July 27, 2020

Clearside Biomedical, Inc. (CLSD) Upgraded to Buy: Here's What You Should Know

Clearside Biomedical, Inc. (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

Yahoo | June 22, 2020

Clearside Biomedical Announces Numerous Presentations at the ARVO 2020 Meeting

– Preclinical CLS-AX data demonstrates a potentially long-acting therapy for neovascular age-related macular degeneration – – Evidence supports the reliability, repeatability,.

Yahoo | June 17, 2020

Read More 'CLSD' Stories Here

CLSD Price Returns

1-mo 39.29%
3-mo 13.37%
6-mo 5.41%
1-year 35.42%
3-year -72.50%
5-year N/A
YTD -32.76%
2019 171.03%
2018 -84.71%
2017 -21.70%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6802 seconds.